Rocket One Inc. Common Stock Q2 2024 Earnings Report

Rocket One Inc. Common Stock EPS Results

• Actual EPS: -$0.24
• Consensus EPS: -$0.39
• Beat/Miss: Beat by +$0.15
• One Year Ago EPS: N/A

Rocket One Inc. Common Stock Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rocket One Inc. Common Stock Announcement Details

• Quarter: Q2 2024
• Date: 8/9/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.